绝经激素治疗的现状与探索

doi:10.6040/j.issn.1671-7554.0.2018.1472

摘要/Abstract

摘要： 更年期是女性的普遍现象。由于卵巢功能减退,引起一系列生理、躯体、精神症状的改变以及一些远期慢性疾病的发生。更年期保健是一项综合措施,对更年期妇女采取合理有效的保健干预,具有重要的临床价值。在过去的十年中,人们对绝经激素治疗(MHT)的理解和治疗方式的选择取得了惊人的进展,这些治疗方式可以有效缓解女性的绝经相关症状。但是由于人们认知的不足,更年期女性保健受到限制。为了推广普及MHT在妇女保健中的作用,我们根据国内外指南规范,参考专家意见,并结合本地特点制定了一套更年期多维保健体系。

关键词: 围绝经期妇女, 绝经激素治疗, 围绝经期保健, 更年期, 激素补充治疗

Abstract: Menopause is a universal event for women. As a result of ovarian dysfunction, it causes changes in physiological, physical, and mental symptoms as well as some long-term chronic diseases. The perimenopausal womens health care is a comprehensive measure. It is very important to take reasonable and effective interventions for perimenopausal women. The past decade has witnessed an amazing progress in the understanding of menopause hormone therapy(MHT)and in the choice of treatment modalities that are available to address the symptom burden of menopause. However, 山东大学学报 (医学版)57卷2期 -周坚红,等.绝经激素治疗的现状与探索 \=-because of scarcity of understanding, the perimenopausal womens health care is limited. In order to promote the role of MHT in womens health care, based on the domestic and international guidelines and expert recommends, we tailored a set of multi-dimensional health care system of menopause to combine with local characteristics.

Key words: Perimenopausal woman, Menopausal hormone therapy, Perimenopausal womens health care, Climacteric, Hormone replacement therapy

中图分类号:

R711.59

周坚红,马麟娟,贾瀛娴,李春明. 绝经激素治疗的现状与探索[J]. 山东大学学报 (医学版), 2019, 57(2): 1-5.

ZHOU Jianhong, MA Linjuan, JIA Yingxian, LI Chunming. Current status and exploration of menopause hormone therapy[J]. Journal of Shandong University (Health Sciences), 2019, 57(2): 1-5.

参考文献

[1] 符书馨, 郁琦. 围绝经期管理的现状和发展[J]. 发育医学电子杂志, 2017, 5(2): 65-67,59.
[2] 谢梅青, 陈蓉, 任慕兰. 中国绝经管理与绝经激素治疗指南(2018)[J]. 协和医学杂志, 2018, 9(6): 512-525.
[3] Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track[J]. N Engl J Med, 2016, 374(9): 803-806.
[4] 中共中央国务院印发《“健康中国2030”规划纲要》. 中华人民共和国国务院公报[EB/OL].(2016-12-25)[2018-12-25]. http://www.gov.cn/gongbao/content/2016/content_5133024.htm.
[5] 吴静. 更年期妇女保健的临床实施方法分析[J]. 中外女性健康研究, 2018(21): 96-97.
[6] Greising SM, Baltgalvis KA, Lowe DA, et al. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci, 2009, 64(10): 1071-1081.
[7] Sriprasert I, Hodis HN, Karim R, et al. Differential effect of plasma estradiol on subclinical atherosclerosis progression in early vs late postmenopause[J]. J Clin Endocrinol Metab, 2019, 104(2): 293-300.
[8] Løkkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy[J]. Maturitas, 2006, 53(2): 226-233.
[9] Imtiaz B, Taipale H, Tanskanen A, et al. Risk of Alzheimers disease among users of postmenopausal hormone therapy: a nationwide case-control study[J]. Maturitas, 2017, 98: 7-13. doi:10.1016/j.maturitas.2017.01.002.
[10] de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy[J]. Maturitas, 2016, 91: 153-155. doi:10.1016/j.maturitas.2016.06.001.
[11] Santen RJ, Stuenkel CA, Burger HG, et al. Competency in menopause management: whither goest the internist?[J]. J Womens Health(Larchmt), 2014, 23(4): 281-285.
[12] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial[J]. JAMA, 2002, 288(3): 321-333.
[13] Rossouw JE, Manson JE, Kaunitz AM, et al. Lessons learned from the Womens Health Initiative trials of menopausal hormone therapy[J]. Obstet Gynecol, 2013, 121(1): 172-176.
[14] Hsieh E, Nunez-Smith M, Henrich JB. Needs and priorities in womens health training: perspectives from an internal medicine residency program[J]. J Womens Health(Larchmt), 2013, 22(8): 667-672.
[15] Gass ML, Stuenkel CA, Utian WH, et al. Use of compounded hormone therapy in the United States: report of the north american menopause society survey[J]. Menopause, 2015, 22(12): 1276-1284.
[16] Lam PM, Leung TN, Haines C, et al. Climacteric symptoms and knowledge about hormone replacement therapy among Hong Kong Chinese women aged 40-60 years[J]. Maturitas, 2003, 45(2): 99-107.
[17] Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause[J]. Endocr Pract, 2011, 17(Suppl 6): 1-25.
[18] North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society[J]. Menopause, 2012, 19(3): 257-271.
[19] ACOG Practice Bulletin No. 141: management of menopausal symptoms[J]. Obstet Gynecol, 2014, 123(1): 202-216.
[20] Reid R, Abramson BL, Blake J, et al. Managing menopause[J]. J Obstet Gynaecol Can, 2014, 36(9): 830-833.
[21] Stuenkel CA, Gass ML, Manson JE, et al. A decade after the womens health initiative: the experts do agree[J]. J Clin Endocrinol Metab, 2012, 97(8): 2617-2618.
[22] Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2015, 100(11): 3975-4011.
[23] Cedars MI. Introduction: menopausal hormone therapy: where are we today?[J]. Fertil Steril, 2014, 101(4): 885-886.
[24] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society[J]. Menopause, 2018, 25(11): 1362-1387.
[25] 康爱琴. 更年期妇女健康状况及影响因素分析[J]. 中国妇幼保健, 2013, 28(2): 283-286.
[26] Collins Fantasia H, Sutherland MA. Hormone therapy for the management of menopause symptoms[J]. J Obstet Gynecol Neonatal Nurs, 2014, 43(2): 226-235.
[27] Toffol E, Kalleinen N, Haukka J, et al. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life[J]. Menopause, 2014, 21(5): 493-500.
[28] Gibson CJ, Mendes WB, Schembri M, et al. Cardiac autonomic function and hot flashes among perimenopausal and postmenopausal women[J]. Menopause, 2017, 24(7): 756-761.
[29] Ruan XY, Cui YM, Du J, et al. Prevalence of climacteric symptoms comparing perimenopausal and postmenopausal Chinese women[J]. J Psychosom Obstet Gynaecol, 2017, 38(3): 161-169.
[30] Stuenkel CA. Menopausal hormone therapy: current considerations[J]. Endocrinol Metab Clin North Am, 2015, 44(3): 565-585.
[31] Lipold LD, Batur P, Kagan RS. Is there a time limit for systemic menopausal hormone therapy?[J]. Cleve Clin J Med, 2016, 83(8): 605-612.
[32] 施玉华. 社区更年期妇女保健探讨[J]. 实用妇科内分泌杂志(电子版), 2018, 5(8): 43,46.
[33] 梁娴. 围绝经期妇女保健的研究进展[J]. 世界最新医学信息文摘(电子版), 2016, 16(57): 37.
[34] 雷浩. 多学科综合管理在更年期妇女保健中的应用效果分析[J]. 世界最新医学信息文摘, 2018, 18(78): 98-99.
[35] Guo MH, Wang MF, Liu MM, et al. Management of cesarean scar pregnancy: a case series[J]. Chin Med Sci J, 2015, 30(4): 226-230.
[36] Wang B, Song Y, Chen Y, et al. Correlation analysis for follicle-stimulating hormone and C-terminal cross-linked telopetides of type I collagen in menopausal transition women with osteoporosis[J]. Int J Clin Exp Med, 2015, 8(2): 2417-22.
[37] Song Y, Wang ES, Xing LL, et al. Follicle-stimulating hormone induces postmenopausal dyslipidemia through inhibiting hepatic cholesterol metabolism[J]. J Clin Endocrinol Metab, 2016, 101(1): 254-263.
[38] Hu JL, Chu KT, Song Y, et al. Higher level of circulating estradiol is associated with lower frequency of cognitive impairment in Southeast China[J]. Gynecol Endocrinol, 2017, 33(11): 840-844.
[39] Lan YB, Huang YZ, Qu F, et al. Time course of global gene expression alterations in Candida albicans during infection of HeLa cells[J]. Bosn J Basic Med Sci, 2017, 17(2): 120-131.
[40] Li CM, Cao MF, Ma LJ, et al. Pyrethroid pesticide exposure and risk of primary ovarian insufficiency in Chinese women[J]. Environ Sci Technol, 2018, 52(5): 3240-3248.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed